Elizabeth S. Klings, MD
Associate Professor
Boston University School of Medicine
Dept of Medicine
Pulmonary, Allergy, Sleep & Critical Care Medicine

MD, New York University School of Medicine




Dr. Klings is an Associate Professor in the Department of Medicine. She is the Director of the Center for Excellence in Sickle Cell Disease and the Director of the Pulmonary Hypertension at BUSM/Boston Medical Center. She has an outpatient clinical practice focused on patients with pulmonary hypertension and those with pulmonary complications of sickle cell disease. She attends in the Medical Intensive Care Unit and on the Pulmonary Hypertension Consultation Service at Boston Medical Center. As Director of the largest sickle cell center in New England, Dr. Klings has created numerous new clinical programs for our patients and has expanded the clinical trials program.

Dr. Klings’ research since fellowship has focused on pathogenesis of pulmonary vascular complications of sickle cell disease. She is an NIH-funded Principal Investigator .in the Pulmonary Center collaborating with numerous other investigators across the medical campus. She has phenotypically screened over 200 sickle cell patients at Boston Medical Center for the presence of pulmonary hypertension and currently investigating the roles of disease modulators including sleep-disordered breathing and venous thromboembolism in the endothelial and vascular dysfunction these patients experience. Known internationally as a leader in the care and treatment of patients with sickle cell disease, she was first author of the American Thoracic Society sponsored clinical guidelines for Diagnosis and Treatment of Pulmonary Hypertension in Sickle Cell Disease. She recently chaired an ATS sponsored workshop to define clinical and research priorities in sickle cell lung disease and serves on the NHLBI Sickle Cell Disease Advisory Committee.

Member
Boston University
Pulmonary Center


Program Director
Boston University
Center of Excellence in Sickle Cell Disease


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research




Protocol #APD811-303: A Study Evaluating the Long-Term Efficacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION
02/06/2019 - 02/06/2022 (PI)
United Therapeutics Corporation


Protocol # STERIO-SCD, A Phase lib Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients with Sickle Cell Diseases
03/20/2018 - 09/19/2021 (Subcontract PI)
University of Pittsburgh Bayer HealthCare


Assessing the effectiveness of anti-sickling agents for sickle hemoglobin and red blood cells
02/01/2016 - 01/31/2021 (PI)
General Hospital Corp d/b/a Massachusetts General Hospital


A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of APD811, an Oral IP Receptor Agonist, in Patients with Pulmonary Arterial Hypertension
12/12/2014 - 12/31/2020 (PI)
Arena Pharmaceuticals Inc.


A StuDy eVAluatiNg the EfficaCy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients
11/30/2018 - 11/30/2020 (PI)
United Therapeutics Corporation


Hematopoietic Stem Cell Transplantation for Young Adults with Sickle Cell Disease
09/01/2015 - 07/31/2020 (Subcontract PI)
Emory University NIH NHLBI
5U01HL128566-03

Protocol # 402-C-1602, An Extended Access Program to Assess Long-Term Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension.
07/27/2017 - 07/26/2020 (PI)
Reata Pharmaceuticals, Inc.


The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi-center, double-blind, placebo
07/15/2015 - 07/14/2020 (PI)
Actelion Pharmaceuticals, Ltd.


Protocol # AC-055-512 RETRO: A Retrospective, multicEnter charT Review to collect dOsing information of PAH background medication in subject who participated in the AC-055-302 (SERAPHIN) double-blind
07/26/2018 - 05/31/2020 (PI)
Actelion Pharmaceuticals, Ltd.


A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Pulmonary Arterial Hypertension
05/30/2014 - 05/31/2020 (PI)
Reata Pharmaceuticals, Inc.


Showing 10 of 30 results. Show All Results


Title


Yr Title Project-Sub Proj Pubs
2013 Protein biomarkers of pulmonary hypertension in sickle cell disease 5R21HL107993-02 3
2012 Protein biomarkers of pulmonary hypertension in sickle cell disease 1R21HL107993-01A1 3
2011 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 5P41RR010888-15-5116 259
2010 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 5P41RR010888-14-6816 259
2009 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 5P41RR010888-13-6167 259
2009 Gene polymorphism in chronic sickle cell lung disease 5K23HL079003-05 7
2008 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 5P41RR010888-12-5241 259
2008 Gene polymorphism in chronic sickle cell lung disease 5K23HL079003-04 7
2007 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 2P41RR010888-11-8062 259
2007 Gene polymorphism in chronic sickle cell lung disease 5K23HL079003-03 7
Showing 10 of 17 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Gupta VK, Strykowski R, Scarpato B, Lawrence R, Khan SL, Patel J, Nouraie SM, Cohen RT, Sloan JM, Klings ES. The effect of anticoagulant choice on venous thromboembolism recurrence and bleeding in sickle cell disease. Am J Hematol. 2020 Jul 03.View Related Profiles. PMID: 32619024
     
  2. Gillmeyer KR, Rinne ST, Glickman ME, Lee KM, Shao Q, Qian SX, Klings ES, Maron BA, Hanlon JT, Miller DR, Wiener RS. Factors Associated With Potentially Inappropriate Phosphodiesterase-5 Inhibitor Use for Pulmonary Hypertension in the United States, 2006 to 2015. Circ Cardiovasc Qual Outcomes. 2020 May; 13(5):e005993.View Related Profiles. PMID: 32393128
     
  3. Schoenberg NC, Argula RG, Klings ES, Wilson KC, Farber HW. Prevalence and Mortality of Pulmonary Hypertension in ESRD: A Systematic Review and Meta-analysis. Lung. 2020 06; 198(3):535-545.View Related Profiles. PMID: 32367414
     
  4. Ruhl AP, Sadreameli SC, Cohen RT, Klings ES. Reply: Ethnically Diverse Normative Data for Diffusing Capacity and Lung Volumes. Ann Am Thorac Soc. 2020 01; 17(1):129-130.View Related Profiles. PMID: 31702938
     
  5. Farrell AT, Panepinto J, Desai AA, Kassim AA, Lebensburger J, Walters MC, Bauer DE, Blaylark RM, DiMichele DM, Gladwin MT, Green NS, Hassell K, Kato GJ, Klings ES, Kohn DB, Krishnamurti L, Little J, Makani J, Malik P, McGann PT, Minniti C, Morris CR, Odame I, Oneal PA, Setse R, Sharma P, Shenoy S. End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. Blood Adv. 2019 12 10; 3(23):4002-4020. PMID: 31809537
     
  6. Cusano J, Curry EJ, Kingston KA, Klings E, Li X. Epidemiology and Perioperative Complications in Patients With Sickle Cell Disease After Orthopaedic Surgery: 26 Years' Experience at a Major Academic Center. J Am Acad Orthop Surg. 2019 Dec 01; 27(23):e1043-e1051.View Related Profiles. PMID: 30889039
     
  7. Ruhl AP, Sadreameli SC, Allen JL, Bennett DP, Campbell AD, Coates TD, Diallo DA, Field JJ, Fiorino EK, Gladwin MT, Glassberg JA, Gordeuk VR, Graham LM, Greenough A, Howard J, Kato GJ, Knight-Madden J, Kopp BT, Koumbourlis AC, Lanzkron SM, Liem RI, Machado RF, Mehari A, Morris CR, Ogunlesi FO, Rosen CL, Smith-Whitley K, Tauber D, Terry N, Thein SL, Vichinsky E, Weir NA, Cohen RT, Klings ES. Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report. Ann Am Thorac Soc. 2019 09; 16(9):e17-e32.View Related Profiles. PMID: 31469310
     
  8. Gillmeyer KR, Lee KM, Shao Q, Miller DR, Maron BA, Klings ES, Rinne ST, Wiener RS. Multisystem Healthcare Use among U.S. Veterans with Pulmonary Hypertension. Ann Am Thorac Soc. 2019 08; 16(8):1072-1074.View Related Profiles. PMID: 31026406
     
  9. Gillmeyer KR, Lee MM, Link AP, Klings ES, Rinne ST, Wiener RS. Response. Chest. 2019 05; 155(5):1077-1078.View Related Profiles. PMID: 31060692
     
  10. Gillmeyer KR, Lee MM, Link AP, Klings ES, Rinne ST, Wiener RS. Accuracy of Algorithms to Identify Pulmonary Arterial Hypertension in Administrative Data: A Systematic Review. Chest. 2019 04; 155(4):680-688.View Related Profiles. PMID: 30471268
     
Showing 10 of 62 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 62 publications over 22 distinct years, with a maximum of 6 publications in 2014

YearPublications
19992
20003
20014
20022
20031
20041
20052
20062
20072
20082
20093
20102
20113
20123
20131
20146
20154
20162
20173
20185
20195
20204
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

anemia, sickle cell
endothelium
pulmonary hypertension

Available to Mentor as: (Review Mentor Role Definitions):
  • Career Mentor
  • Co-Mentor or Peer Mentor
  • Diversity Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:

72 E. Concord St Housman (R)
Boston MA 02118
Google Map


Klings's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department